Roche, MorphoSys Plan Experimental Clinical Trials of Gantenerumab for Alzheimer’s

Roche, MorphoSys Plan Experimental Clinical Trials of Gantenerumab for Alzheimer’s
Roche and MorphoSys will partner on experimental Phase 3 clinical trials to study the effectiveness and safety of gantenerumab in patients with early to mild Alzheimer's disease. Roche, a Swiss global healthcare company, will start preparing two studies soon, according to MorphoSys, a German biotechnology company that developed gantenerumab. The trials will start this year, MorphoSys added. Gantenerumab is an antibody against the beta-amyloid protein that accumulates in the neurons of people with Alzheimer’s. MorphoSys used its proprietary HuCAL antibody library technology to develop the therapy. HuCAL allows scientists to make rapid discoveries of antibodies that can be tested against several diseases, including Alzheimer's, cancer and rheumatoid arthritis. "This is great news for MorphoSys,” Marlies Sproll, the company’s chief scientific officer, said in a press release. “We are delighted by the strong commitment to gantenerumab as a potential new therapy for Alzheimer's disease." "The HuCAL-derived antibody gantenerumab has properties that we believe make it a promising candidate to treat Alzheimer's disease, and we look forward to learning more about these new phase 3 trials," Sproll added. Roche and MorphoSys were partners on another Phase 3 trial, SCarletRoAD (NCT01224106), which investigated the effectiveness and safety of gantenerumab in patients with early Alzheimer's. The partners  <
Subscribe or to access all post and page content.